Log in

OTCMKTS:HKMPFHikma Pharmaceuticals Stock Price, Forecast & News

$27.50
0.00 (0.00 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$27.50
Now: $27.50
$27.50
50-Day Range
$27.50
MA: $29.41
$32.00
52-Week Range
$19.75
Now: $27.50
$42.00
Volume20 shs
Average Volume1,018 shs
Market Capitalization$6.66 billion
P/E Ratio18.33
Dividend YieldN/A
Beta0.44
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals. The Generics segment develops and sells oral and other non-injectable generic products for retail market. The Branded segment develops, manufactures, and markets branded generics and in-licensed products to retail and hospital markets. The company offers products in various therapeutic areas, including respiratory, oncology, pain management, anti-infectives, cardiovascular, diabetes, and central nervous system. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Read More
Hikma Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.69 out of 5 stars


Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:HKMPF
CUSIPN/A
CIKN/A
Phone44-20-7399-2760

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.21 billion
Cash Flow$1.87 per share
Book Value$8.79 per share

Profitability

Miscellaneous

Employees8,600
Market Cap$6.66 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive HKMPF News and Ratings via Email

Sign-up to receive the latest news and ratings for HKMPF and its competitors with MarketBeat's FREE daily newsletter.

Hikma Pharmaceuticals (OTCMKTS:HKMPF) Frequently Asked Questions

How has Hikma Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Hikma Pharmaceuticals' stock was trading at $24.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HKMPF shares have increased by 12.2% and is now trading at $27.50. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Hikma Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Hikma Pharmaceuticals.

Has Hikma Pharmaceuticals been receiving favorable news coverage?

News headlines about HKMPF stock have been trending neutral this week, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hikma Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Hikma Pharmaceuticals.

Who are some of Hikma Pharmaceuticals' key competitors?

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the following people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 62)
  • Mr. Mazen Samih Taleb Darwazah, Exec. Vice Chairman & Pres of MENA (Age 61)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 50)
  • Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 47)
  • Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPF."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Hikma Pharmaceuticals' stock price today?

One share of HKMPF stock can currently be purchased for approximately $27.50.

How big of a company is Hikma Pharmaceuticals?

Hikma Pharmaceuticals has a market capitalization of $6.66 billion and generates $2.21 billion in revenue each year. The company earns $486 million in net income (profit) each year or $1.50 on an earnings per share basis. Hikma Pharmaceuticals employs 8,600 workers across the globe.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is www.hikma.com.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR. The company can be reached via phone at 44-20-7399-2760 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.